Johan M. Kros
A5075152654- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Ferroptosis and cancer prognosis
- Cancer, Hypoxia, and Metabolism
- Epigenetics and DNA Methylation
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- Meningioma and schwannoma management
- RNA modifications and cancer
- RNA Research and Splicing
- Neuroblastoma Research and Treatments
- MRI in cancer diagnosis
- Chromatin Remodeling and Cancer
- Lung Cancer Research Studies
- Ubiquitin and proteasome pathways
- Histone Deacetylase Inhibitors Research
- Molecular Biology Techniques and Applications
- Angiogenesis and VEGF in Cancer
- Hedgehog Signaling Pathway Studies
- MicroRNA in disease regulation
- Ocular Oncology and Treatments
- Lung Cancer Treatments and Mutations
- Pituitary Gland Disorders and Treatments
- Cancer Immunotherapy and Biomarkers
Erasmus MC
2016-2025
Erasmus University Rotterdam
2015-2024
Erasmus MC Cancer Institute
2015-2024
Codarts Rotterdam
2010-2019
University Medical Center Utrecht
2003-2017
Emory University Hospital
2017
Princess Margaret Cancer Centre
2017
University of Zurich
2017
Center for Neuro-Oncology
2017
Dana-Farber Cancer Institute
2017
Epigenetic silencing of the MGMT (O6-methylguanine–DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients glioblastoma who receive alkylating agents.
Anaplastic oligodendroglioma are chemotherapy-sensitive tumors. We now present the long-term follow-up findings of a randomized phase III study on addition six cycles procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy (RT).Adult patients with newly diagnosed anaplastic oligodendroglial tumors were randomly assigned either 59.4 Gy RT or same followed by adjuvant PCV. An exploratory analysis correlation between 1p/19q status survival was part study. Retrospectively,...
Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogeneity, at least four distinct molecular variants, previous attempts to identify targets for therapy have been underpowered because of small samples sizes. Here we report somatic copy number aberrations (SCNAs) in 1,087 unique...
Gliomas are the most common primary brain tumors with heterogeneous morphology and variable prognosis. Treatment decisions in patients rely mainly on histologic classification clinical parameters. However, differences between subclasses grades subtle, classifying gliomas is subject to a large interobserver variability. To improve current standards, we have performed gene expression profiling cohort of glioma samples all subtypes grades. We identified seven distinct molecular subgroups that...
Approximately 50% of glioblastomas (GBMs) are characterized by overexpression the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In approximately 25% instances, constitutively activated mutants present. These observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM.In randomized, controlled, phase II trial, 110 patients with progressive GBM after prior radiotherapy were randomly assigned to either erlotinib or control arm that received...
Major discoveries in the biology of nervous system tumors have raised question how non-histological data such as molecular information can be incorporated into next World Health Organization (WHO) classification central tumors. To address this question, a meeting neuropathologists with expertise diagnosis was held Haarlem, Netherlands, under sponsorship International Society Neuropathology (ISN). Prior to meeting, participants solicited input from clinical colleagues diverse...
The management of patients with brain metastases has become a major issue due to the increasing frequency and complexity diagnostic therapeutic approaches. In 2014, European Association Neuro-Oncology (EANO) created multidisciplinary Task Force draw evidence-based guidelines for from solid tumors. Here, we present these guidelines, which provide consensus review evidence recommendations diagnosis by neuroimaging neuropathology, staging, prognostic factors, different treatment options....
Recent studies have shown the prognostic significance of IDH1 mutations in glioma. It is yet unclear if are predictive for outcome to chemotherapy. We determined effect on progression-free survival and overall (OS), its correlation with other clinical molecular features prospective randomized European Organization Research Treatment Cancer study 26951 adjuvant procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, vincristine (PCV) anaplastic oligodendroglioma.IDH1 IDH2 alterations...
Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection, histologic variant. Stark prognostic genetic differences among the subgroups suggest that subgroup-specific biomarkers could improve prognostication.Molecular were identified from a discovery set 673 medulloblastomas 43 cities around world. Combined risk stratification models...
Extensive resections in low-grade glioma (LGG) are associated with improved overall survival (OS). However, World Health Organization (WHO) classification of gliomas has been completely revised and is now predominantly based on molecular criteria. This requires reevaluation the impact surgery molecularly defined LGG subtypes.We included 228 adults who underwent since 2003 for a supratentorial LGG. Pre- postoperative tumor volumes were assessed semiautomatic software T2-weighted images....
Pseudo-TORCH syndrome (PTS) is characterized by microcephaly, enlarged ventricles, cerebral calcification, and, occasionally, systemic features at birth resembling the sequelae of congenital infection but in absence an infectious agent. Genetic defects resulting activation type 1 interferon (IFN) responses have been documented to cause Aicardi-Goutières syndrome, which a PTS. Ubiquitin-specific peptidase 18 (USP18) key negative regulator I IFN signaling. In this study, we identified...
The Consortium to Inform Molecular and Practical Approaches CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) World Health Organization (WHO) grade II or III present with (i) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or (ii) gain of chromosome 7 combined loss 10, (iii) epidermal growth factor receptor (EGFR) amplification should be reclassified as astrocytic glioma, IDH1/2...
Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah™ and Yescarta™) were recently approved by the FDA. Kymriah™ is for treatment of pediatric patients young adults with refractory or relapse (R/R) B precursor acute lymphoblastic leukemia Yescarta™ adult R/R large lymphoma. In common, both are CD19-specific CAR lysing CD19-positive targets. Their dramatic efficacy in short term has been highlighted many media reports. By contrast, their glaring safety gaps behind miracles...
Purpose: Oligodendroglial tumors are chemotherapy-sensitive tumors, with two thirds of patients responding to combination chemotherapy procarbazine, lomustine, and vincristine (PCV). Temozolomide (TMZ), a new alkylating methylating agent, has demonstrated high response rates in recurrent anaplastic astrocytoma. We investigated TMZ as first-line oligodendroglial (OD) mixed oligoastrocytomas (OA) after surgery radiation therapy. Patients Methods: In prospective, nonrandomized, multicenter,...
The role of dopamine agonist treatment in corticotroph pituitary tumors is controversial. aim this study was to evaluate D2 receptor expression 20 and correlate it the vitro effect agonists on ACTH secretion vivo short-term cabergoline cortisol secretion. evaluated by receptor-ligand binding, immunohistochemistry, RT-PCR. A 50% or more decrease daily urinary levels considered a significant clinical response. At specific binding [125I]epidepride found 80% cases. immunostaining 75% 83.3% cases...
Purpose O6-methylguanine-methyltransferase (MGMT) promoter methylation has been shown to predict survival of patients with glioblastomas if temozolomide is added radiotherapy (RT). It unknown MGMT also predictive outcome RT followed by adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligodendroglial tumors (AOT). Patients Methods In the European Organisation for Research Treatment Cancer study 26951, 368 AOT were randomly assigned either alone or PCV. From...